echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: The effect of glucocorticoids on the prognosis of patients with large B-cell lymphoma treated with CAR-T cell therapy

    Blood: The effect of glucocorticoids on the prognosis of patients with large B-cell lymphoma treated with CAR-T cell therapy

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Although chimeric antigen receptor (CAR) T cell therapy has achieved a high remission rate in patients with relapsed or refractory large B-cell lymphoma (LBCL), less than 40% of patients can maintain long-term remission


    Although chimeric antigen receptor (CAR) T cell therapy has achieved a high remission rate in patients with relapsed or refractory large B-cell lymphoma (LBCL), less than 40% of patients can maintain long-term remission of lymphoma CAR- T management

    Glucocorticoids are commonly used to manage the severe toxicity associated with CAR T cell therapy.


    The newly published " Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma " in the "Blood" magazine explored the effects of glucocorticoids on the recurrence or recurrence of standard anti-CD19 CAR-T cell therapy.


    Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

    A total of 100 patients were evaluated, of which 60 (60%) received glucocorticoid therapy to manage toxic reactions related to CAR-T cell therapy


    Effect of glucocorticoid on PFS and OS of patients

    Effect of glucocorticoid on PFS and OS of patients

    After a median follow-up of 10 months, a higher cumulative dose of glucocorticoids was associated with a significantly shorter progression-free survival


    A higher cumulative dose of glucocorticoids is associated with a significantly shortened progression-free survival.


    When managing the toxicity related to CAR-T cell therapy, the use of glucocorticoids should be controlled at the lowest dose and shortest duration as much as possible, and their activation time should be postponed as much as possible in the clinically feasible situation.


    Original source:

    Strati Paolo,Ahmed Sairah,Furqan Fateeha et al.


    Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.